BioWorld

Dec. 29, 2004

View Archived Issues

ImmunoGen, Centocor Partner In Potential $43.5M TAP Deal

ImmunoGen Inc. licensed certain rights to its Tumor-Activated Prodrug (TAP) technology to Centocor Inc. in a deal worth up to $43.5 million, plus royalties. (BioWorld Today) Read More

ALZA Files For Approval Of Premature Ejaculation Drug

Read More

In Heart Tissue Engineering, It's Electricity, Gap, Scaffolds

Read More

Emisphere Accesses Cash Via Equity Deal, Revises Elan Debt

Read More

Other News To Note

Read More

Appointments And Advancements

Read More